ABOUT CVRx
Company OverviewCVRx is a private company located in Minneapolis, Minnesota. The company has developed proprietary active implantable technology for the treatment of high blood pressure, also referred to as hypertension, that cannot be controlled with medications ( resistant hypertension). The CVRx senior management and technical team have many years of experience commercializing implantable medical devices. The company is well financed and supported by an outstanding board of directors. They have established a world-class scientific advisory board, which includes thought leading physicians and scientists in the field of hypertension.
Hypertension affects over 73 million people in the United States and is estimated to cause 1 in every 8 deaths worldwide. It is a major risk factor for cardiovascular disease, morbidity and mortality. It is a costly disease and yearly costs to treat hypertension in the United States are estimated to be $69.4 billion. Approximately 25 percent of people with hypertension cannot adequately control their hypertension with medications and lifestyle modifications. It is a disease that needs new treatment solutions.
The CVRx product provides a "physiological rational" method to reduce blood pressure. The Rheos® Hypertension System uses the CVRx patented Baroreflex Activation TherapyTM (BATTM) technology to trigger the body's own natural blood pressure regulation system. CVRx has a strong intellectual property foundation, which will protect the unique hypertension therapy the company is developing. This product is currently under clinical evaluation in Europe and the United States.
Just use your browser's print button - the page will print without the site interface.